Intercell plans additional Pseudomonas trial, Novartis delays option decision
This article was originally published in Scrip
Executive Summary
Intercell, Europe's leading independent vaccine developer, has unveiled plans to run an additional efficacy trial of its candidate Pseudomonas aeruginosa vaccine. The move, which is being financially supported by its development partner Novartis, will delay the pharma company's decision whether to opt-in into the programme. The new Phase II trial will be powered to show efficacy in intensive care unit patients.